🇺🇸 FDA

Company profile · Sponsor

PROVECTUS

PROVECTUS BIOPHARMACEUTICALS, INC.

PVCT · NYSE biotech KNOXVILLE, TN, USA
Pipeline
12
Drugs
0
Patents
8

Quick answer

PROVECTUS (PVCT) is a biotech company. headquartered in KNOXVILLE, TN, USA. listed on NYSE. NovaPharmaNews links 12 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker PVCT
Exchange NYSE
Company type biotech
Headquarters KNOXVILLE, TN, USA
SEC CIK 0000315545

Pipeline (12)

Search pipeline →

  1. PV-10 (10% rose bengal disodium)

    PROVECTUS

    Cutaneous Melanoma

    phase 3 small molecule terminated

    1 trial

  2. PH-10

    PROVECTUS

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  3. PH-10 (0.001% Rose Bengal)

    PROVECTUS

    Psoriasis

    phase 2 small molecule completed

    1 trial

  4. PH-10 (0.002% Rose Bengal)

    PROVECTUS

    Psoriasis

    phase 2 small molecule completed

    1 trial

  5. PH-10 (rose bengal disodium 0.001%)

    PROVECTUS

    Plaque Psoriasis

    phase 2 small molecule terminated

    1 trial

  6. PV-10

    PROVECTUS

    Melanoma

    phase 2 small molecule active

    2 trials

  7. PV-10 (10% rose bengal disodium)

    PROVECTUS

    Melanoma

    phase 2 small molecule completed

    1 trial

  8. Topical Rose Bengal, 0.005%

    PROVECTUS

    Psoriasis

    phase 2 small molecule completed

    1 trial

  9. PV-10 (10% rose bengal disodium)

    PROVECTUS

    Cancer Metastatic to the Liver

    phase 1 small molecule active

    1 trial

  10. PV-10 (rose bengal disodium 10%)

    PROVECTUS

    Breast Cancer

    phase 1 small molecule completed

    1 trial

  11. PV-10 (rose bengal disodium, 10%)

    PROVECTUS

    Melanoma

    phase 1 small molecule completed

    1 trial

  12. Rose bengal disodium

    PROVECTUS

    Neuroendocrine Tumors Metastatic to the Liver

    phase 1 small molecule active

    1 trial

Patents (8)

Search patents →

  1. US 12377068

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12133840

    Halogenated xanthene composition and method for treating hematologic cancers

    Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12064507

    Composition and method for oral treatment of leukemia

    Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11975106

    Uses of halogenated xanthenes in oncology and virology

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11974980

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11938182

    Halogenated xanthenes as vaccine adjuvants

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11426379

    Combination of local and systemic therapies for enhanced treatment of dermatologic conditions

    Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11419844

    Halogenated xanthene composition and method for treating hematologic cancers

    Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is PROVECTUS?

PROVECTUS (PVCT) is a biotech company. headquartered in KNOXVILLE, TN, USA. listed on NYSE. NovaPharmaNews links 12 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does PROVECTUS sponsor?

We track 12 ClinicalTrials.gov-linked programs for PROVECTUS, including PV-10 (10% rose bengal disodium) and 11 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does PROVECTUS company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.